CD19 and acute lymphoblastic leukemia: Similar conclusions can be drawn from other clinical trials, in which patients with relapsed or refractory ALL received anti-CD19 agents before CART treatment, with even 90% of patients achieving complete remission (Gardner et al. 2017; Jacoby et al. 2018).